ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company revolutionizing healthcare through its exosome-based technology, announced today that its Co-Founder, Dr. Atta ...
Lonza agreed to provide cGMP manufacturing and technical support for commercial scale production of RION’s Purified Exosome Product™ (PEP) drug substance for late phase clinical supply and beyond.
RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of RION Vet, a veterinary biotechnology company advancing a ...
Rion, founded in Rochester in 2017, plans to build a new manufacturing facility in a 10,000-square-foot space in Building 103 on the Rochester Technology Campus by the end of 2024 or early in 2025.
ROCHESTER — Rion, Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense will use a $2.4 million grant from the U.S. Department of Defense to research treatments for soldiers ...
RION LAUNCHES RION VET TO TRANSFORM ANIMAL HEALTH WITH FIRST-IN-CLASS BIOLOGIC THERAPEUTIC; APPOINTS INDUSTRY LEADER MARK HERTHEL AS CEO; ANNOUNCES SERIES A FULFILLMENT RION, a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results